Genprex expands gene therapy manufacturing

By The Science Advisory Board staff writers

June 16, 2020 -- Genprex has expanded its program to manufacture tumor suppressor candidate 2 (TUSC2) with a new manufacturing agreement with partner Aldevron.

Under the agreement, Aldevron will produce TUSC2 plasmid DNA, the active ingredient for the Genprex's lead immunogene therapy candidate, Oncoprex. The commercial-scale manufacturing efforts will enable Genprex to significantly lower costs per unit of product manufactured.

The manufactured TUSC2 plasmid DNA will be encapsulated with a lipid nanoparticle to form Oncoprex. According to preclinical data, the drug should induce cell signaling that triggers programmed cell death and modulation of the immune system when transfected into cancer cells.

Genprex's upcoming phase I/II clinical trial of Oncoprex will be combined with osimertinib for non-small cell lung cancer (NSCLC). Osimertinib, which is marketed by AstraZeneca as Tagrisso, received fast track designation in January and the trial is expected to be started in early 2021. A combination trial with Oncoprex and Keytruda in NSCLC is also planned for the near future.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here